Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Adenocarcinoma Cells
100%
Esophageal Adenocarcinoma
100%
Foretinib
100%
ERK Phosphorylation
30%
Lapatinib
30%
MET Signaling
30%
Expression Level
20%
Induced Apoptosis
20%
Small Interfering RNA (siRNA)
20%
Small Molecule Inhibitors
20%
AKT1
20%
ERK Pathway
20%
Growth Inhibition
20%
C-Met
20%
OE33
20%
HER2 Signaling
20%
Esophageal Cancer
10%
Signaling Pathway
10%
Western Blot Analysis
10%
Tumor Cells
10%
Cell Growth
10%
Akt Phosphorylation
10%
AKT Pathway
10%
Ectopic Expression
10%
Overexpression
10%
Combination Therapy
10%
Plasmid
10%
Mediated Growth
10%
Phosphorylation
10%
Downstream Signaling
10%
Phosphorylation State
10%
Apoptotic Pathway
10%
Reduced Sensitivity
10%
Knock
10%
Effects on Growth
10%
Genomic Studies
10%
Gene Overexpression
10%
Growth Signaling
10%
Transient Effect
10%
HER2 Overexpression
10%
HER2 Expression
10%
Cell Inhibition
10%
HER2 Amplification
10%
Cell Growth Inhibition
10%
ErbB1
10%
Phosphorylated Akt
10%
MET Expression
10%
HER2 mutation
10%
MET Protein Expression
10%
MET Gene Amplification
10%
Biochemistry, Genetics and Molecular Biology
Protein Kinase B
100%
Programmed Cell Death
60%
Lapatinib
60%
Growth Inhibition
60%
Cell Growth
40%
Small Molecule
40%
Small Interfering RNA
40%
Genomics
20%
Western Blot
20%
Ectopic Expression
20%
Plasmid
20%
Gene Amplification
20%
Gene Overexpression
20%
Medicine and Dentistry
Esophageal Adenocarcinoma
100%
Foretinib
100%
Protein Kinase B
50%
Programmed Cell Death
30%
Growth Inhibition
30%
Lapatinib
30%
Cell Growth
20%
Small Interfering RNA
20%
Cell Line
10%
Esophageal Cancer
10%
Combination Therapy
10%
Tumor Cell
10%
Gene Amplification
10%
Epidermal Growth Factor Receptor 2
10%
Western Blot
10%
Plasmid
10%
Cell Signaling Pathway
10%
Ectopic Expression
10%
Scatter Factor Receptor
10%
Gene Overexpression
10%
OE33 Cell Line
10%
Esophageal Adenocarcinoma Cell Line
10%
Pharmacology, Toxicology and Pharmaceutical Science
Esophageal Adenocarcinoma
100%
Foretinib
100%
Protein Kinase B
50%
Lapatinib
30%
Small Interfering RNA
20%
Neoplasm
10%
Western Blot
10%
Combination Therapy
10%
Esophagus Cancer
10%
Epidermal Growth Factor Receptor 2
10%
Scatter Factor Receptor
10%